1. Obituary of Professor Fumimaro Takaku: a tribute to a real leader in medicine in Japan (1931–2022)

   • Akio Urabe

   In Memoriam 24 May 2022 Pages: 759 - 759

   

2. Guest Editorial: Innovation will be a bridge to cure in patients with multiple myeloma?

   • Hiroyuki Takamatsu

   Progress in Hematology 11 May 2022 Pages: 760 - 761

3. Multiple myeloma with high-risk cytogenetics and its treatment approach

   • Ichiro Hanamura

   Progress in Hematology Open access 09 May 2022 Pages: 762 - 777

   

4. Progress of modern imaging modalities in multiple myeloma

   • Toshiki Terao
   • Kosei Matsue

   Progress in Hematology 09 May 2022 Pages: 778 - 789

   

5. Bringing mass spectrometry into the care of patients with multiple myeloma

   • David L. Murray

   Progress in Hematology 26 April 2022 Pages: 790 - 798

   

6. Novel immunotherapies in multiple myeloma

   • Ken Ohmine
   • Ryosuke Uchibori

   Progress in Hematology 18 May 2022 Pages: 799 - 810

   

7. Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group

   • Yuki Fujiwara
   • Tomohiro Urata
   • Yasushi Hiramatsu

   Rapid Communication 18 May 2022 Pages: 811 - 815

   

8. T cell clonal expansion and STAT3 mutations: a characteristic feature of acquired chronic T cell-mediated pure red cell aplasia

   • Fumihiro Kawakami
   • Toru Kawakami
   • Fumihiro Ishida

   Original Article 11 March 2022 Pages: 816 - 825

   

9. The balance of comprehensive coagulation and fibrinolytic potential is disrupted in patients with moderate to severe COVID-19

   • Tomoko Onishi
   • Naruto Shimonishi
   • Keiji Nogami

   Original Article 16 February 2022 Pages: 826 - 837

   

10. Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis

    • Naoto Takahashi
    • Jorge E. Cortes
    • Tim H. Brümmendorf

    Original Article 02 March 2022 Pages: 838 - 851

    

11. Erythroblast predominance without CD41/cyCD41-positive blasts predicts favorable prognosis in patients with myelodysplastic syndromes and acute myeloid leukemias treated with azacitidine

    • Akihito Matsuoka
    • Masaki Tanibuchi
    • Teruhisa Taoka

    Original Article 11 March 2022 Pages: 852 - 859

    

12. Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors

    • Yoriko Yamashita-Kashima
    • Keigo Yorozu
    • Yasushi Yoshimura

    Original Article 18 March 2022 Pages: 860 - 872

    

13. Unrelated cord blood transplantation for adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders

    • Yasushi Onishi
    • Koichi Onodera
    • Hideo Harigae

    Original Article 10 March 2022 Pages: 873 - 881

    

14. The safety and efficacy of hematopoietic stem cell mobilization using biosimilar filgrastim in related donors

    • Riko Tsumanuma
    • Eijiro Omoto
    • Hiromasa Yabe

    Original Article 09 April 2022 Pages: 882 - 889

    

15. JACLS ALL-02 SR protocol reduced-intensity chemotherapy produces excellent outcomes in patients with low-risk childhood acute lymphoblastic leukemia

    • Yoshihiro Takahashi
    • Hisashi Ishida
    • Keizo Horibe

    Original Article 08 March 2022 Pages: 890 - 897

    

16. Paravertebral extramedullary hematopoiesis in a case of myelodysplastic syndrome with ring sideroblasts and an SF3B1 mutation

    • Chie Asou
    • Tomoya Maeda
    • Norio Asou

    Case Report 28 January 2022 Pages: 898 - 901

    

17. Bosutinib-induced lung injury: a report of two cases and literature review

    • Naoki Watanabe
    • Tomoiku Takaku
    • Miki Ando

    Case Report 28 February 2022 Pages: 902 - 905

    

18. Hemophilic pseudotumor of the maxillary sinus in an inhibitor-positive patient with hemophilia A receiving emicizumab: a case report

    • Fuko Kawahara
    • Rie Shirayama
    • Koichi Kusuhara

    Case Report 25 January 2022 Pages: 906 - 912

    

19. Patients with B-cell lymphoma receiving anti-CD20 monoclonal antibody-containing chemotherapies and seroreactive patterns in response to COVID-19 vaccination

    • Tohru Inaba
    • Keita Okumura
    • Yoko Nukui

    Letter to the Editor 12 April 2022 Pages: 913 - 914

20. Interactions with the CYP3A inhibitor voriconazole differ between extended-LCP- and immediate-release tacrolimus formulations

    • Gerold Thölking
    • Ulrich Jehn
    • Stefan Reuter

    Letter to the Editor 09 April 2022 Pages: 915 - 915

21. Correction to: Patients with B-cell lymphoma receiving anti-CD20 monoclonal antibody-containing chemotherapies and seroreactive patterns in response to COVID-19 vaccination

    • Tohru Inaba
    • Keita Okumura
    • Yoko Nukui

    Correction 05 May 2022 Pages: 916 - 917